RIBBON-2: Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

WANG  Xiao-jia; QIAN  Xue-ke

doi:10.3969/j.issn.1671-5144.2012.03.017

WANG Xiao-jia, QIAN Xue-ke. RIBBON-2: Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 153-156. DOI: 10.3969/j.issn.1671-5144.2012.03.017

Citation:

WANG Xiao-jia, QIAN Xue-ke. RIBBON-2: Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 153-156. DOI: 10.3969/j.issn.1671-5144.2012.03.017

Citation:

WANG Xiao-jia, QIAN Xue-ke. RIBBON-2: Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 153-156. DOI: 10.3969/j.issn.1671-5144.2012.03.017

RIBBON-2: Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Abstract

FullText(HTML)

References (7)

RIBBON-2: Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Catalog

Export File

Citation

Format

Content